Valuation: Axonics, Inc.

Capitalization 3.63B 3.07B 2.81B 2.67B 4.95B 329B 5.17B 32.71B 12.95B 158B 13.61B 13.33B 570B P/E ratio 2022
-48.9x
P/E ratio 2023 -502x
Enterprise value 3.31B 2.8B 2.57B 2.43B 4.52B 300B 4.72B 29.85B 11.82B 144B 12.41B 12.16B 520B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
3 years 47.59
Extreme 47.59
71.05
5 years 38.41
Extreme 38.41
79.92
10 years 11.95
Extreme 11.95
79.92
More quotes
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 30/09/2013
Director of Finance/CFO 41 01/10/2023
Chief Operating Officer 47 31/07/2018
Director TitleAgeSince
Director/Board Member 69 31/01/2018
Chairman 55 28/04/2020
Director/Board Member 74 07/04/2019
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.75%-.--%-.--%+20.65% 3.63B
-1.14%-3.05%-8.46%+31.51% 137B
-2.05%+2.01%+26.51%+7.97% 14.65B
-2.30%+7.65%-14.66%-63.78% 6.53B
-0.88%-5.75%-26.50%+127.22% 6.46B
-1.06%-2.97%+40.86%+33.36% 2.91B
-1.18%-1.64%-1.65%-18.99% 2.09B
+0.15%-13.30%-63.93%-73.68% 1.91B
Average -0.96%-1.62%-5.98%+8.03% 21.9B
Weighted average by Cap. -1.20%-2.32%-5.96%+27.57%
See all sector performances

Financials

2022 2023
Net sales 274M 232M 212M 201M 373M 24.8B 390M 2.47B 977M 11.94B 1.03B 1.01B 42.97B 366M 310M 284M 269M 500M 33.19B 523M 3.3B 1.31B 15.98B 1.37B 1.35B 57.52B
Net income -59.7M -50.53M -46.32M -43.87M -81.45M -5.41B -85.16M -538M -213M -2.6B -224M -219M -9.37B -6.09M -5.15M -4.72M -4.47M -8.31M -552M -8.68M -54.89M -21.73M -266M -22.83M -22.36M -956M
Net Debt -348M -295M -270M -256M -475M -31.54B -497M -3.14B -1.24B -15.18B -1.31B -1.28B -54.65B -317M -269M -246M -233M -433M -28.75B -453M -2.86B -1.13B -13.84B -1.19B -1.17B -49.82B
More financial data * Estimated data
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
797
More about the company